Form 4: Bio-Rad Laboratories Executive Acquires Stock Options

Timothy S. Ernst, EVP, General Counsel & Secretary of Bio-Rad Laboratories, acquired 2,357 non-qualified stock options on March 8, 2024.

Summary

• On March 8, 2024, Timothy S. Ernst, EVP, General Counsel & Secretary of Bio-Rad Laboratories, acquired 2,357 non-qualified stock options.
• The exercise price of these options is $343.76.
• The options vest over four years, at a rate of 25% per year, starting on the anniversary of the grant date.
• The expiration date for these options is March 8, 2034.
• Following the transaction, Mr. Ernst directly owns 2,357 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation, and does not contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The acquisition of stock options by an executive can be seen as a positive sign, aligning the executive's interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and life sciences industries, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Thermo Fisher Scientific and Danaher also utilize stock options as part of their executive compensation plans.
• The vesting schedule of 25% per year is a typical vesting arrangement for stock options.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates